Relyea Zuckerberg Hanson LLC Trims Holdings in Pfizer Inc. (NYSE:PFE)

Relyea Zuckerberg Hanson LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 11.2% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 9,506 shares of the biopharmaceutical company’s stock after selling 1,196 shares during the quarter. Relyea Zuckerberg Hanson LLC’s holdings in Pfizer were worth $241,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in PFE. Rialto Wealth Management LLC purchased a new position in Pfizer during the fourth quarter worth approximately $26,000. Clarity Asset Management Inc. purchased a new position in Pfizer during the fourth quarter worth approximately $27,000. Gould Capital LLC raised its position in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer in the fourth quarter valued at $28,000. Finally, Bernard Wealth Management Corp. purchased a new stake in Pfizer in the fourth quarter valued at $30,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of a number of research analyst reports. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price on the stock. The Goldman Sachs Group restated a “neutral” rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, UBS Group lifted their price objective on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Trading Down 1.3%

PFE opened at $24.51 on Friday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The stock has a market capitalization of $139.35 billion, a price-to-earnings ratio of 17.38, a PEG ratio of 0.64 and a beta of 0.57. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business has a fifty day moving average price of $23.06 and a 200 day moving average price of $24.96.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. During the same period in the previous year, the firm posted $0.82 EPS. Pfizer’s revenue for the quarter was down 7.8% on a year-over-year basis. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were paid a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.02%. Pfizer’s payout ratio is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.